Bsense Bio Therapeutics Ltd. has nominated BSEN-760, a dual Kv7.2/3 and TRPV1 ion channel modulator, as a clinical candidate for the treatment of chronic pain.
SAN DIEGO, Jan. 6, 2026 /PRNewswire/ -- HUYABIO International today announced favorable Phase 1 clinical data for HBI-3000, a novel bioinspired investigational drug with promising antiarrhythmic ...
Ion channels are attractive drug targets due to their importance in health and disease, but finding ways to target a specific ion channel selectively is a major challenge. Now, researchers have ...
When a scrappy team of scientists joined forces in the late 1990s, they sought to identify genetic mutations that could have an outsized impact on the treatment of human disease. At the time, that ...
Researchers have found that manipulating voltage patterns of tumor cells -- using ion channel blockers already FDA-approved as treatments for other diseases -- can in fact significantly reduce ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--SiteOne Therapeutics, Inc., a biopharmaceutical company developing selective ion channel modulators for the treatment of pain, cough, and other conditions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results